2.55

3.77% -0.10

After Hours: 2.58 0.03 +1.18%

Heron Therapeutics Inc (HRTX)

Overview News Price History Option Chain Why HRTX Down? Discussions Forecast Stock Split

Heron Therapeutics Inc stock is currently priced at $2.55, with a 24-hour trading volume of 2.18M. It has seen a -3.77% decreased in the last 24 hours and a -13.56% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.72 pivot point. If it approaches the $2.50 support level, significant changes may occur.

Previous Close:

$2.65

Open:

$2.66

24h Volume:

2.18M

Market Cap:

$383.34M

Revenue:

$127.04M

Net Income/Loss:

$-110.56M

P/E Ratio:

-2.1795

EPS:

-1.17

Net Cash Flow:

$-60.33M

1W Performance:

-5.90%

1M Performance:

-13.56%

6M Performance:

+275.39%

1Y Performance:

+1.19%

1D Range:

$2.46

$2.66

52W Range:

$0.50

$3.22

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name

Heron Therapeutics Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

858-251-4400

Address

4242 Campus Point Court, Suite 200, San Diego, CA

Employee

145

Twitter

Next Earnings Date

2024-05-15

Latest SEC Filings

HRTX's Discussions on Twitter

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-27-20	Initiated	Guggenheim	Buy
Feb-20-20	Reiterated	Needham	Buy
Jan-16-19	Reiterated	Needham	Buy
Apr-05-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Reiterated	Mizuho	Buy
Mar-01-18	Reiterated	Needham	Buy
Jan-03-18	Initiated	Leerink Partners	Outperform
Sep-27-17	Initiated	Northland Capital	Outperform
Feb-27-17	Initiated	Needham	Buy
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy
Sep-23-15	Reiterated	Leerink Partners	Outperform
Sep-02-15	Initiated	BofA/Merrill	Buy
Aug-03-15	Reiterated	Brean Capital	Buy
Jun-30-15	Reiterated	JMP Securities	Mkt Outperform
Jun-19-15	Reiterated	Leerink Partners	Outperform
Aug-07-14	Initiated	Noble Financial	Buy

View All

Heron Therapeutics Inc Stock (HRTX) Latest News

Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?

Benzinga

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics

Zacks Investment Research

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Zacks Investment Research

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Heron Therapeutics Inc Stock (HRTX) Financials Data

Heron Therapeutics Inc (HRTX) Revenue 2024

HRTX reported a revenue (TTM) of $127.04 million for the quarter ending December 31, 2023, a +17.99% rise year-over-year.

Heron Therapeutics Inc (HRTX) Net Income 2024

HRTX net income (TTM) was -$110.56 million for the quarter ending December 31, 2023, a +39.26% increase year-over-year.

Heron Therapeutics Inc (HRTX) Cash Flow 2024

HRTX recorded a free cash flow (TTM) of -$60.33 million for the quarter ending December 31, 2023, a +59.44% increase year-over-year.

Heron Therapeutics Inc (HRTX) Earnings per Share 2024

HRTX earnings per share (TTM) was -$0.84 for the quarter ending December 31, 2023, a +51.45% growth year-over-year.

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.